Article
KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Cancer - 15 Feb 2013
Mao Chen, Huang Ya-Fang, Yang Zu-Yao, Zheng Da-Yong, Chen Jin-Zhang, Tang Jin-Ling
Abstract excerpt
BACKGROUND: The authors conducted a systematic review and meta-analysis to examine whether patients who had metastatic colorectal cancer (mCRC) with the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G13D mutation (an amino acid substitution at position 13 in KRAS from a glycine to an aspartic acid) and received cetuximab treatment had better clinical outcomes than patients who had mCRC tumors with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.